BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31849044)

  • 1. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
    Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
    Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
    Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the standard of care for low-grade serous ovarian cancer.
    Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
    Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-grade epithelial ovarian cancer: what a radiologist should know.
    Elsherif S; Javadi S; Viswanathan C; Faria S; Bhosale P
    Br J Radiol; 2019 Mar; 92(1095):20180571. PubMed ID: 30604635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment.
    Ciucci A; Zannoni GF; Buttarelli M; Martinelli E; Mascilini F; Petrillo M; Ferrandina G; Scambia G; Gallo D
    Oncotarget; 2016 Oct; 7(42):68033-68043. PubMed ID: 27462782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.
    Johnson RL; Laios A; Jackson D; Nugent D; Orsi NM; Theophilou G; Thangavelu A; de Jong D
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
    Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.